9:34 AM
 | 
Mar 16, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AM-Pharma's Phase II sepsis readout triggers Pfizer's takeout option

AM-Pharma B.V. (Bunnik, the Netherlands) reported mixed data from the Phase II STOP-AKI trial of recAP to treat sepsis-associated acute kidney injury (AKI). The readout marks the start of an option period under which Pfizer Inc. (NYSE:PFE) may buy out AM-Pharma.

On the 301-patient trial's primary endpoint, once-daily IV recAP for three days failed to significantly improved kidney function as measured by...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >